34 / 154
S4
A B S T R A C T S
Disclosure of interest:
None declared
S07
PROSTATE
Jean-Pierre Droz
Centre Léon-Bérard, Environment and Cancer Reasearch Unit, Lyon,
France
Context:
Prostate cancer is a disease of the senior adults,
the most frequent cancer in men. It requires specific urologic
and geriatric managements.
Objective:
To update the 2010 and 2014 SIOG (International
Society of Geriatric Oncology) guidelines on prostate cancer
in senior adult patients aged more than 70 years. The 2016
updates include the health status evaluation; the treatment
of localized disease; and the treatment of advanced disease,
particularly new active agents in the treatment of castration
refractory disease.
Methods:
In 2016, a new multidisciplinary SIOG task force
was formed to update the recommendations. A systematic
review of articles published in 2014–2016 was performed.
The search strategy was based mainly on the terms “prostate
cancer”, “elderly”, and different key words on local treatment
and drugs. The terms “castration refractory/resistant” was
added as were used terms on geriatric evaluation. Each expert
of the Writing Committee included proposed modifications,
the material was managed by the first author, the manuscript
circulated to the experts of the Review Committee which
included their inputs and finally the manuscript was prepared
to obtain a consensus of experts.
Results:
The geriatric evaluation is based on a three step
screening of health problems: 1) cognitive screening test
and a global screening test, the G8; 2) if Mini-COG abnormal
patients should have complete cognitive evaluation; if
G8 abnormal the patient is referred to the next step: 2) a
simplified geriatric evaluation based on physical dependence,
comorbidities, and nutrition; 3) Patients are classified in four
health status groups: fit, frail, disabled/ severe comorbidities,
too sick. Geriatric intervention should reverse some problems
but requires CGA. The major treatment conclusion is that fit
and some frail patients are likely to benefit from the same
treatments than younger, treatment adaptations are required
in the other patients group.
Conclusions:
Many refinements in geriatric evaluation,
localized disease treatments techniques, role of surveillance
and “watch and see policy”, medical management of advanced
disease by new drugs participate to a refined decision making
process. Treatment decisions should be based on health
status evaluation (mainly driven by the severity of associated
comorbidities) rather than age, and also on patient preference.
Disclosure of interest:
Board member: Sanofi
S08
CANCER IN MOROCCAN ELDERLY: THE FIRST
MULTICENTRIC TRANSVERSAL STUDY EXPLORING THE
SOCIO-DEMOGRAPHIC AND ECONOMIC PROFILE OF
MOROCCAN ELDERLY CANCER PATIENTS
Hassan Errihani
Mohamed V University, Medical oncology, Rabat, Morocco
Introduction:
The Moroccan population’s life expectancy
has increased and so is behaving the incidence of cancer
in elderly. We launched the first Moroccan prospective
multicentric transversal study, to explore the subgroup of
Moroccan elderly cancer patients.
Material and methods:
The study was conducted in 10 civil
and military, Medical Oncology Departments in Morocco.
Patients were enrolled between June 15th and October 15th,
2015.The inclusion criteria were patients aged 65 years or over
having a proven solid cancer at any stage. The questionnaire
used in the study included four sections: General socio-
demographic and economic data, daily habits, Medical history
including the G8 test and the EORTC- QLQC30 questionnaire.
The questionnaire was administered once for each patient
included. All the patients signed an informed consent. The
study was approved by the ethical committee of Rabat. A
comparison will be made between the subgroups 65–70 years
old and
71 years old. More than 150 patients were enrolled.
The final results will be presented at the Congress.
Conclusion:
This is the first muticentric prospective study
designed to have an insight on the medical, sociodemographic
and economic profile of Moroccan elderly cancer patients.
This kind of studies could be considered as the first step in
developing an adapted geriatric assessment in Morocco.
Disclosure of interest:
None declared
S09
PALLIATIVE CARE FOR OLDER CANCER PATIENTS IN
EUROPE
Marilène Filbet
CHU Lyon, Medecine palliative, Lyon, France
Most of the people who die in Europe are older than 65 years
old and this number will increase in the next decade. The
need for palliative care for older patients will increase equally,
and that leads WHO and EAPC to propose a guide for better
palliative care for older people (WHO 2004). We don’t have
any recommendations for older people with cancer, and this
lack needs to be filled. Palliative care services are unequally
developed within European countries (C. Centeno, EAPC task
force), and so are the long-term services for older people. The
development of the geriatric oncology will improve cancer
survival, and this disease trajectory will become like the
trajectory of the chronic diseases: people will have a long life
expectancy. This presentation will describe the patients and
family needs during the palliative stage of the cancer disease,
and the services available across European countries.